drugset
drugset / Trial / NCT04783181

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

NCT04783181 ↗

Phase 1/2 Active not recruiting 8 enrolled Adrenas Therapeutics Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.

Timeline

Start
2021-07-01
Primary completion
2029-02
Completion
2029-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BBP-631 Gene therapy (AAV / viral vector) — Intravenous

Indications

classic congenital adrenal hyperplasia